摘要
Type 2 cytokines are usually predominant in tumor patients and associated with tumor progression.To explore whether reversing of type 2 predominance could be a promising strategy in tumor immunotherapy,PBMCs of 35 lung cancer patients and 19 healthy subjects were prepared and subjected to be examined for cytokine secretion and gene expression.Tetra-Methylpyrazine (TTMP),extracted from a traditional Chinese medicinal herb which has been used in clinic to reverse the Th2 status of cancer patients in China,was added to PBMC culture. Determined by RT-PCR,the positive percentages of mRNA expression of type 1 cytokines (8.6% for IFN-γ and 11.4% for IL-2) were lower than those of type 2 cytokines (71.4% for IL-4,60% for IL-6 and 80% for 1L-10) in patients' PBMCs.The potential of gene expressing (measured as relative intensity to the ratio of β-actin) in the patients for type 1 cytokines was also in a low level (0.111 for IFN-γ,0.119 for IL-2) in comparison with a relative high level for type 2 cytokines (0.319 for IL-4,0.303 for IL-6 and 0.377 for IL-10).Meanwhile,both positive percentage and relative intensity of gene expression were lower for a type 1 cytokine-related transcription factor T-bet (31.4% and 0.142,respectively) than those for type 2 cytokine-related GATA3 (85.7% and 0.378, respectively).The blood serum levels of IFN-γ and IL-2 in the patients were slightly lower but not significantly when compared with healthy control.In contrast,the levels IL-4 and IL-6 in patients were significantly higher than those in healthy subjects by ELISA analysis.TTMP could enhance supernatant concentration and gene expression levels of IFN-γ,IL-2 and T-bet,but reduced those of type 2 cytokines.These results demonstrate that the lung cancer patients had a predominant expression of type 2 cytokines and TTMP could reverse the type 2 dominant status,which might offer an alternative therapeutic regime for lung cancer patients.Cellular & Molecular Immunology.2004;1(1):63-70.
Type 2 cytokines are usually predominant in tumor patients and associated with tumor progression.To explore whether reversing of type 2 predominance could be a promising strategy in tumor immunotherapy,PBMCs of 35 lung cancer patients and 19 healthy subjects were prepared and subjected to be examined for cytokine secretion and gene expression.Tetra-Methylpyrazine (TTMP),extracted from a traditional Chinese medicinal herb which has been used in clinic to reverse the Th2 status of cancer patients in China,was added to PBMC culture. Determined by RT-PCR,the positive percentages of mRNA expression of type 1 cytokines (8.6% for IFN-γ and 11.4% for IL-2) were lower than those of type 2 cytokines (71.4% for IL-4,60% for IL-6 and 80% for 1L-10) in patients' PBMCs.The potential of gene expressing (measured as relative intensity to the ratio of β-actin) in the patients for type 1 cytokines was also in a low level (0.111 for IFN-γ,0.119 for IL-2) in comparison with a relative high level for type 2 cytokines (0.319 for IL-4,0.303 for IL-6 and 0.377 for IL-10).Meanwhile,both positive percentage and relative intensity of gene expression were lower for a type 1 cytokine-related transcription factor T-bet (31.4% and 0.142,respectively) than those for type 2 cytokine-related GATA3 (85.7% and 0.378, respectively).The blood serum levels of IFN-γ and IL-2 in the patients were slightly lower but not significantly when compared with healthy control.In contrast,the levels IL-4 and IL-6 in patients were significantly higher than those in healthy subjects by ELISA analysis.TTMP could enhance supernatant concentration and gene expression levels of IFN-γ,IL-2 and T-bet,but reduced those of type 2 cytokines.These results demonstrate that the lung cancer patients had a predominant expression of type 2 cytokines and TTMP could reverse the type 2 dominant status,which might offer an alternative therapeutic regime for lung cancer patients.Cellular & Molecular Immunology.2004;1(1):63-70.
基金
supported partly by 0utstanding Young Scientist Award(#30125038)
Key Project(#30230340)by Natural Science Foundation of China
Chinese Key Basic Science Program by Ministry of Science and Technology of China(#2001CB510009)
Foundation of Chinese Academy of Science(#KSCX2-2-08)
UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant.